Our industry briefing brings together highlights from the global CBD, cannabis and hemp industries. In this week’s briefing we include World-first Trial to Assess Cannabis-based Drug for Treatment of Aggressive Brain Tumours; Heritage Cannabis Partners with Avicanna to Commericalize Topical CBD Products; Akerna Sees Revenue Rise 63% in Latest Financial Results; and GW Pharma Receives Approval from UK’s MHRA for Treatment of seizures Associated with Tuberous Sclerosis Complex.
For daily updates visit our dedicated news site cannyxnews.com.
Image | Unsplash.com
A UK University has announced plans to conduct a trial to assess the efficacy of cannabis-based drug Sativex in treating the most aggressive form of brain tumours.
The trial which will be led by the University of Birmingham, will assess whether Sativex when added to the current standard chemotherapy treatment (temozolomide) could offer extra time to live for adults diagnosed with a recurrence of their glioblastoma after initial treatment.
Image | Pexels.com
Avicanna and Heritage Cannabis have entered into an exclusive intellectual property licensing and royalty agreement for the commercialization of several Avicanna’s evidence-based CBD topical products. The deal will see Avicanna’s formulations used under Heritage’s medical cannabis brands targeting patients registered to purchase medical cannabis in Canada.
Image | Google.com
Cannabis enterprise software specialist Akerna has announced second quarter results for 2021, with software revenue up 56%, and total revenue up 63% year-over-year.
The developer of the cannabis industry’s first seed-to-sale enterprise resource planning (ERP) software technology (MJ Platform) also increased gross profit by 153% from, the same period in 2020 to USD $3million. The company’s net loss was $6.1million which remains flat with the same period last year.
Image | GW Pharma
GW Pharmaceuticals has received approval form the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for a new indication for GW’s cannabidiol (EPIDYOLEX) as an adjunctive treatment of seizures associated with tuberous sclerosis complex (TSC), for patients two years of age and older.
Get insider access to the global CBD, Cannabis and Hemp industries at CANNYX News